Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer
Reads0
Chats0
TLDR
In this article, a reference ranking of all survival related genes in chemotherapy treated basal and estrogen positive/HER2 negative breast cancer was presented, and the results help to neglect those with unlikely clinical significance and focus future research on the most promising candidates.Abstract:
Introduction Extensive research is directed to uncover new biomarkers capable to stratify breast cancer patients into clinically relevant cohorts. However, the overall performance ranking of such marker candidates compared to other genes is virtually absent. Here, we present the ranking of all survival related genes in chemotherapy treated basal and estrogen positive/HER2 negative breast cancer. Methods We searched the GEO repository to uncover transcriptomic datasets with available follow-up and clinical data. After quality control and normalization, samples entered an integrated database. Molecular subtypes were designated using gene expression data. Relapse-free survival analysis was performed using Cox proportional hazards regression. False discovery rate was computed to combat multiple hypothesis testing. Kaplan-Meier plots were drawn to visualize the best performing genes. Results The entire database includes 7,830 unique samples from 55 independent datasets. Of those with available relapse-free survival time, 3,382 samples were estrogen receptor-positive and 696 were basal. In chemotherapy treated ER positive/ERBB2 negative patients the significant prognostic biomarker genes achieved hazard rates between 1.76 and 3.33 with a p value below 5.8E−04. The significant prognostic genes in adjuvant chemotherapy treated basal breast cancer samples reached hazard rates between 1.88 and 3.61 with a p value below 7.2E−04. Our integrated platform was extended enabling the validation of future biomarker candidates. Conclusions A reference ranking for all genes in two chemotherapy treated breast cancer cohorts is presented. The results help to neglect those with unlikely clinical significance and to focus future research on the most promising candidates.read more
Citations
More filters
Journal ArticleDOI
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition
Peng Liu,Zehao Wang,Xueqi Ou,Peng Wu,Yue Zhang,Song Wu,Xiangsheng Xiao,Yuehua Li,Feng Ye,Hailin Tang +9 more
TL;DR: In this paper , the authors used RT-qPCR and FISH assays to confirm circEZH2 existence, characteristics, and expression in liver metastatic breast cancer.
Journal ArticleDOI
The Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells
Jiliang Wang,Wei Chen,Ling Zuo,Midie Xu,Yong Wu,Jiami Huang,Xu Fang Zhang,Yong-hong Li,Jing Wang,Jing Chen,Husheng Wang,Huizhen Sun +11 more
TL;DR: This study highlights the need to investigate the underlying mechanisms of chemotherapy resistance and develop novel potential therapeutic targets for ovarian cancer therapy failure.
Journal ArticleDOI
Sublethal cytochrome c release generates drug-tolerant persister cells
Halime Kalkavan,Mark J. Chen,Jeremy Chase Crawford,Giovanni Quarato,Patrick Fitzgerald,Stephen W.G. Tait,Colin R. Goding,Douglas R. Green +7 more
TL;DR: In this article , the authors found that sub-lethal mitochondrial outer membrane permeabilization (MOMP) and holocytochrome release are key requirements for the generation of the persister phenotype.
Journal ArticleDOI
Role of miR-2392 in driving SARS-CoV-2 infection.
J. Tyson McDonald,Francisco J. Enguita,Deanne Taylor,Deanne Taylor,Robert J. Griffin,Waldemar Priebe,Mark R. Emmett,Mohammad M. Sajadi,Anthony D. Harris,Jean Clement,Joseph M Dybas,Nukhet Aykin-Burns,Joseph W Guarnieri,Larry N. Singh,Peter Grabham,Stephen B. Baylin,Aliza Yousey,Andrea N Pearson,Peter M. Corry,Amanda M. Saravia-Butler,Thomas R. Aunins,Sadhana Sharma,Prashant Nagpal,Cem Meydan,Jonathan Foox,Christopher Mozsary,Bianca Cerqueira,Viktorija Zaksas,Urminder Singh,Eve Syrkin Wurtele,Sylvain V. Costes,Gustavo Gastão Davanzo,Diego Galeano,Alberto Paccanaro,Alberto Paccanaro,Suzanne L Meinig,Robert S. Hagan,Natalie M. Bowman,Matthew C. Wolfgang,Selin Altinok,Nicolae Sapoval,Todd J. Treangen,Pedro M. Moraes-Vieira,Charles R. Vanderburg,Douglas C. Wallace,Douglas C. Wallace,Jonathan C. Schisler,Christopher E. Mason,Anushree Chatterjee,Robert Meller,Afshin Beheshti,Afshin Beheshti +51 more
TL;DR: In this article, the authors show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease 2019 infection.
Journal ArticleDOI
Role of p38 MAP kinase in cancer stem cells and metastasis
TL;DR: The p38 mitogen-activated protein kinase (p38 MAPK) is downstream of several CSC-specific signaling pathways and plays an important role in CSC development and maintenance and contributes to metastasis and chemoresistance as discussed by the authors .
References
More filters
Journal ArticleDOI
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
TL;DR: By following this protocol, investigators are able to gain an in-depth understanding of the biological themes in lists of genes that are enriched in genome-scale studies.
Journal ArticleDOI
Cancer statistics, 2020.
TL;DR: Slow momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers, and it is notable that long‐term rapid increases in liver cancer mortality have attenuated in women and stabilized in men.
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
Triple-negative breast cancer.
TL;DR: Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer.